Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Faron Doses First HMA-failed MDS Patient with Bexmarilimab in BEXMAB Trial
Details : FP-1305 (bexmarilimab), a CLEVER-1 binder, is in Phase 1/2 trials with azacitidine and venetoclax for treating acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
September 01, 2024
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Data from Phase 1 BEXMAB Study in Higher-Risk MDS and r/r AML
Details : FP-1305 (bexmarilimab) is a first-in-class, humanized mAb that binds to Clever-1, an immunosuppressive receptor on macrophages, being evaluated for high-risk myelodysplastic syndrome.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
March 18, 2024
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
BEXMAB Data Analysis Provides Insights into HMA-Failed MDS Patient Profiles
Details : FP-1305 (bexmarilimab) is a monoclonal antibody binding to Clever-1, currently in phase 1/2 for treating acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
January 25, 2024
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, which is investigated for the treatment of relapsed/refractory AML and HMA-refractory MmDS patients.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
November 10, 2023
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia
Details : U.S. FDA has granted Orphan Drug Designation to Faron Pharmaceuticals' wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia. ODD will further help bexmarilimab program by offering clinical development and commercialization benefit...
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
August 29, 2023
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system).
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
July 19, 2023
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS
Details : FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, which is investigated for the treatment of relapsed/refractory AML and HMA-refractory MmDS patients.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
June 11, 2023
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The conclusion from analysis is that, when used together, IFNy and TNFa are highly predictive of response to bexmarilimab (P < 0.0001), and patients with low IFNy and TNFa levels experienced significantly higher clinical benefit following treatment with ...
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
September 03, 2022
Lead Product(s) : Bexmarilimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FP-1305 (bexmarilimab) is Faron's wholly-owned, investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid cell function.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : Bexmarilimab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexmarilimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Of 11 patients, 4 experienced clinical benefit - 1 patient had a partial response after two cycles of bexmarilimab (tumor growth reduced by 40% from baseline) but was discontinued before a confirmatory scan was performed. 3 patients had stable disease.
Product Name : FP-1305
Product Type : Antibody
Upfront Cash : Inapplicable
April 21, 2022
Lead Product(s) : Bexmarilimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable